Live Quote · NASDAQAPREHealthcare· Biotechnology

Aprea Therapeutics, Inc.

$0.74 0.55%($-0.00)
TickerSpark Score
53/100
Mixed
80
Valuation
20
Profitability
50
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APRE research report →

52-Week Range12% of range
Low
$0.55
Current
$0.74
High
$2.22
Company Overviewatrinpharma.com

About the company

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways.

CEO
Oren Gilad
IPO
2019
Employees
8
HQ
Boston, MA, US

Price Chart

-56.41% · this period
$2.08$1.33$0.59Jul 02Dec 31Jul 02
Valuation
Market Cap
$4.81M
P/E
-0.48
P/S
40.75
P/B
0.13
EV/EBITDA
3.49
Div Yield
0.00%
Profitability
Gross Margin
-1523.59%
Op Margin
-10649.87%
Net Margin
-10121.69%
ROE
-59.54%
ROIC
-29.38%
Growth & Income
Revenue
$0 · -100.00%
Net Income
$-12,599,569 · 2.77%
EPS
$-1.93 · 17.87%
Op Income
$-13,233,836
FCF YoY
4.99%
Performance & Tape
52W High
$2.22
52W Low
$0.55
50D MA
$0.83
200D MA
$0.98
Beta
1.56
Avg Volume
209.72K

Get TickerSpark's AI analysis on APRE

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 16, 26Grissinger Michaelother12,555
Jun 16, 26Grissinger Michaelother3,135
Jun 16, 26Gruia Gabrielaother12,555
Jun 16, 26Gruia Gabrielaother3,135
Jun 16, 26Peters Richardother12,555
Jun 16, 26Peters Richardother3,135
Jun 16, 26HENNEMAN JOHN B IIIother3,135
Jun 16, 26HENNEMAN JOHN B IIIother12,555
Jun 16, 26BIZZARI JEAN-PIERREother12,555
Jun 16, 26BIZZARI JEAN-PIERREother3,135
Coverage · APRE

Our APRE coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on APRE yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate APRE report →
Internal Compare

Similar companies

Peers in the same neighborhood.